GUTS - Rasio utang marang kapitalisasi buku Fractyl Health Inc.

Logo grafis Fractyl Health Inc. (GUTS)

Global logistics and sanctions risks may hinder the development of Fractyl Health, Inc. (GUTS). However, innovations in endoscopy for diabetes treatment are strengthening physician confidence. The company's debt load relative to its balance sheet capital illustrates this balance, where the value of 0.00 reflects this status. Despite scientific progress, the business relies on reserves, as a stable operating cash flow has not yet been established.

GUTS (Fractyl Health, Inc) riwayat Utang marang nilai buku saka 21.02.2024 nganti 28.10.2026
Barang utama Fractyl

This indicator determines the degree of the business's dependence on borrowed capital relative to its own balance sheet equity. The calculation reflects the proportion of debt obligations to the value of net assets, measuring the issuer's financial stability. By analyzing the history of debt-to-capitalization ratios, an investor assesses the risk of insolvency. For Fractyl Health, Inc. (GUTS), this is critical, as the aggressive expansion of pharma behemoths in diabetes therapy requires immense resources. The balance between loans and equity here determines the company's ability to survive in a fiercely competitive environment.

Pesaing Fractyl Health, Inc. (GUTS)

Utang-utang marang kapitalisasi buku ASND (Ascendis Pharma A/S)|madrigalpharma.com - Utang-utang marang kapitalisasi buku|Rasio utang marang kapitalisasi buku Corcept Therapeutics Incorporated (CORT)|RYTM: Rasio utang marang aset resik|AKRO (Akero Therapeutics Inc) - Rasio utang marang kapitalisasi buku|Metsera Therapeutics (MTSR) - Utang marang nilai buku|MLTX (MoonLake Immunotherapeutics) - Utang-utang marang kapitalisasi buku|Utang-utang marang kapitalisasi buku crinetics.com (CRNX)|NewAmsterdam Pharma Company N.V. (NAMS) - Utang marang nilai buku|Rasio utang marang aset resik SLNO (Soleno Therapeutics Inc)|Amicus Pharma - Rasio utang marang kapitalisasi buku|Utang marang nilai buku 89bio Pharma ETNB|AGIO (Agios Pharmaceuticals) - Utang-utang marang kapitalisasi buku|structuretx.com (GPCR) - Utang-utang marang nilai buku|MDXG - Utang marang nilai buku|Rezolute Inc (RZLT) - Utang marang modal buku|LXRX (Lexicon Pharma) - Utang-utang marang kapitalisasi buku|Utang-utang marang kapitalisasi buku MBX Corp|Utang-utang marang kapitalisasi buku Altimmune, Inc. (ALT)|Rasio utang marang kapitalisasi buku AARD (aardvarktherapeutics.com)|SGMT: Rasio utang marang kapitalisasi buku|BioAge Labs - Utang-utang marang nilai buku|BMEA - Rasio utang marang kapitalisasi buku|QNCX - Rasio utang marang kapitalisasi buku|vtvtherapeutics.com - Utang-utang marang kapitalisasi buku|ATPC (Agape ATP) - Utang-utang marang aset resik|PLUR: Rasio utang marang kapitalisasi buku|Utang-utang marang aset resik SYBX|Rasio utang marang kapitalisasi buku LPCN (Lipocine Corp)|Utang marang nilai buku matinasbiopharma.com (MTNB)|Spruce Biosciences, Inc. (SPRB) - Utang-utang marang kapitalisasi buku|galecto.com - Rasio utang-utang marang kapitalisasi buku|Rasio utang marang kapitalisasi buku Carmell (CTCX)|LUMO - Rasio utang marang aset resik|ONVO: Utang-utang marang kapitalisasi buku|Radius Pharmaceuticals (RDUS) - Utang-utang marang kapitalisasi buku